|
|
 Previous Article | Table of Contents | Next Article 
Wilms' Tumor Gene (WT1) Competes With Differentiation-Inducing
Signal in Hematopoietic Progenitor Cells
Kazushi Inoue,
Hiroya Tamaki,
Hiroyasu Ogawa,
Yoshihiro Oka,
Toshihiro Soma,
Toyoshi Tatekawa,
Yusuke Oji,
Akihiro Tsuboi,
Eui
Ho Kim,
Manabu Kawakami,
Tetsu Akiyama,
Tadamitsu Kishimoto, and
Haruo Sugiyama
From the Departments of Medicine III and of Clinical Laboratory
Science, Osaka University Medical School, Osaka, Japan; and The
Research Institute for Microbial Diseases, Osaka University, Osaka,
Japan.
The WT1 gene is a tumor-suppressor gene that was isolated as a gene
responsible for Wilms' tumor, a childhood kidney neoplasm. We have
previously reported that the WT1 gene is strongly expressed in leukemia
cells with an increase in its expression levels at relapse and an
inverse correlation between its expression levels and prognosis, thus
making it a novel tumor marker for leukemic blast cells. Furthermore,
WT1 antisense oligomers have been found to inhibit the growth of
leukemic cells. These results strongly suggested the involvement of the
WT1 gene in human leukemogenesis. The present study was performed to
prove our hypothesis that the WT1 gene plays a key role in
leukemogenesis and performs an oncogenic function in hematopoietic
progenitor cells, rather than a tumor-suppressor gene function. 32D
cl3, an interleukin-3-dependent myeloid progenitor cell line,
differentiates into mature neutrophils in response to granulocyte
colony-stimulating factor (G-CSF). However, when transfected wild-type
WT1 gene was constitutively expressed in 32D cl3, the cells stopped
differentiating and continued to proliferate in response to G-CSF. As
for signal transduction mediated by G-CSF receptor (G-CSFR), Stat3
was constitutively activated in wild-type WT1-infected 32D cl3 in
response to G-CSF, whereas, in WT1-uninfected 32D cl3, activation of
Stat3 was only transient. However, most interesting was the fact
that G-CSF stimulation resulted in constitutive activation of Stat3
only in wild-type WT1-infected 32D cl3, but not in WT1-uninfected 32D
cl3. Thus, WT1 expression constitutively activated both Stat3 and
Stat3. A transient activation of Stat1 was detected in both
wild-type WT1-infected and uninfected 32D cl3 after G-CSF stimulation,
but no difference in its activation was found. No activation of MAP
kinase was detected in both wild-type WT1-infected and uninfected 32D
cl3 after G-CSF stimulation. These results demonstrated that WT1
expression competed with the differentiation-inducing signal mediated
by G-CSFR and constitutively activated Stat3, resulting in the blocking
of differentiation and subsequent proliferation. Therefore, the data
presented here support our hypothesis that the WT1 gene plays an
essential role in leukemogenesis and performs an oncogenic function in
hematopoietic progenitor cells and represent the first demonstration of
an important role of the WT1 gene in signal transduction in
hematopoietic progenitor cells.
Blood, Vol. 91 No. 8 (April 15), 1998:
pp. 2969-2976
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. Guglielmelli, R. Zini, C. Bogani, S. Salati, A. Pancrazzi, E. Bianchi, F. Mannelli, S. Ferrari, M.-C. Le Bousse-Kerdiles, A. Bosi, et al.
Molecular Profiling of CD34+ Cells in Idiopathic Myelofibrosis Identifies a Set of Disease-Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1)
Stem Cells,
January 1, 2007;
25(1):
165 - 173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Simpson, E. A. Burwell, K. A. Thompson, S. Shahnaz, A. R. Chen, and D. M. Loeb
The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy
Blood,
June 15, 2006;
107(12):
4695 - 4702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nishida, N. Hosen, T. Shirakata, K. Kanato, M. Yanagihara, S.-i. Nakatsuka, Y. Hoshida, T. Nakazawa, Y. Harada, N. Tatsumi, et al.
AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1
Blood,
April 15, 2006;
107(8):
3303 - 3312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Lapillonne, A. Renneville, A. Auvrignon, C. Flamant, A. Blaise, C. Perot, J.-L. Lai, P. Ballerini, F. Mazingue, S. Fasola, et al.
High WT1 Expression After Induction Therapy Predicts High Risk of Relapse and Death in Pediatric Acute Myeloid Leukemia
J. Clin. Oncol.,
April 1, 2006;
24(10):
1507 - 1515.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Oka, A. Tsuboi, T. Taguchi, T. Osaki, T. Kyo, H. Nakajima, O. A. Elisseeva, Y. Oji, M. Kawakami, K. Ikegame, et al.
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
PNAS,
September 21, 2004;
101(38):
13885 - 13890.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Oji, Y. Miyoshi, E. Kiyotoh, S. Koga, Y. Nakano, A. Ando, N. Hosen, A. Tsuboi, M. Kawakami, K. Ikegame, et al.
Absence of Mutations in the Wilms' Tumor Gene WT1 in Primary Breast Cancer
Jpn. J. Clin. Oncol.,
February 1, 2004;
34(2):
74 - 77.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Alberta, G. M. Springett, H. Rayburn, T. A. Natoli, J. Loring, J. A. Kreidberg, and D. Housman
Role of the WT1 tumor suppressor in murine hematopoiesis
Blood,
April 1, 2003;
101(7):
2570 - 2574.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Bellantuono, L. Gao, S. Parry, S. Marley, F. Dazzi, J. Apperley, J. M. Goldman, and H. J. Stauss
Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL
Blood,
November 15, 2002;
100(10):
3835 - 3837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Scheibenbogen, A. Letsch, E. Thiel, A. Schmittel, V. Mailaender, S. Baerwolf, D. Nagorsen, and U. Keilholz
CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia
Blood,
August 28, 2002;
100(6):
2132 - 2137.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Loeb, D. Korz, M. Katsnelson, E. A. Burwell, A. D. Friedman, and S. Sukumar
Cyclin E Is a Target of WT1 Transcriptional Repression
J. Biol. Chem.,
May 24, 2002;
277(22):
19627 - 19632.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Miyoshi, A. Ando, C. Egawa, T. Taguchi, Y. Tamaki, H. Tamaki, H. Sugiyama, and S. Noguchi
High Expression of Wilms' Tumor Suppressor Gene Predicts Poor Prognosis in Breast Cancer Patients
Clin. Cancer Res.,
May 1, 2002;
8(5):
1167 - 1171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. A. Elisseeva, Y. Oka, A. Tsuboi, K. Ogata, F. Wu, E. H. Kim, T. Soma, H. Tamaki, M. Kawakami, Y. Oji, et al.
Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies
Blood,
May 1, 2002;
99(9):
3272 - 3279.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Gao, I. Bellantuono, A. Elsasser, S. B. Marley, M. Y. Gordon, J. M. Goldman, and H. J. Stauss
Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1
Blood,
April 1, 2000;
95(7):
2198 - 2203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Oka, K. Udaka, A. Tsuboi, O. A. Elisseeva, H. Ogawa, K. Aozasa, T. Kishimoto, and H. Sugiyama
Cancer Immunotherapy Targeting Wilms' Tumor Gene WT1 Product
J. Immunol.,
February 15, 2000;
164(4):
1873 - 1880.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
